From November 11–13, 2024, MEDICA Düsseldorf, one of the world’s largest and most prestigious medical industry trade fairs, took place in Düsseldorf Germany. Creative Biosciences, a leading company in China’s molecular diagnostics industry, showcased its flagship product Colosafe® which is a stool DNA test for colorectal cancer screening, along with its innovative automated solutions. The company’s booth attracted significant crowd from professionals worldwide.

During the exhibition, CreativeBio’s booth was abuzz with activity. The Colosafe^® stool DNA test, known for its accuracy, convenience, and non-invasive approach, emerged as a star charisma. By analyzing genetic abnormalities in tumor cells shed in feces, this advanced screening technology aids physicians in detecting early colorectal cancer, offering the potential to halt the disease at its earliest stages and achieve prevention and cure.

To date, Colosafe^® has successfully obtained regulatory approvals in 42 countries and regions across Asia, Europe, South America, and Africa. With ongoing market promotion and substantial sales collaborations, the product has achieved extensive global market coverage, further fortifying CreativeBio’s position as a leader in the molecular diagnostics field.

The company’s presence at MEDICA 2024 underscores its commitment to advancing early cancer detection and expanding its footprint in the international healthcare market.

In addition to Colosafe® , CreativeBio also unveiled its Automatic Sample Preprocessing Instrument and Automatic Nucleic Acid Extraction Instrument, delivering an integrated solution from sample preparation to nucleic acid extraction. These innovations provide robust support for clinical diagnostics. Notably, the Fully Automatic Nucleic Acid Extraction Instrument made its debut at this event. This state-of-the-art instrument combines advanced automation, intelligence, and precision to streamline nucleic acid extraction and purification. Featuring an optimized workflow and a cutting-edge automated operating platform, it significantly reduces the complexity of traditional manual extraction processes, enhancing both efficiency and the reliability of experimental results.

CreativeBio’s automated solutions demonstrate the company’s commitment to driving innovation in molecular diagnostics and advancing clinical testing capabilities worldwide.

Automatic Sample Preprocessing Instrument

Automatic Nucleic Acid Extraction Instrument

The event was not only an industry celebration but also a fruitful journey for CreativeBio. During the exhibition, the company engaged in in-depth exchanges and collaborations with international clients and experts. Many global customers expressed strong interest in CreativeBio’s innovative technologies and indicated their willingness to collaborate. Several partnerships were established, laying a solid foundation for the company’s continuing expansion and business development in the European market.

CreativeBio remains steadfast in its noble vision of “Human Health, My Mission”. The company is dedicated to driving innovation in in vitro diagnostic technologies for early cancer detection, improving global healthcare, and contributing to the well-being of humanity.